AxoGen, Inc. (NASDAQ:AXGN) CEO Karen L. Zaderej Sells 39,280 Shares

AxoGen, Inc. (NASDAQ:AXGN) CEO Karen L. Zaderej sold 39,280 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total value of $301,670.40. Following the transaction, the chief executive officer now owns 1,124,565 shares of the company’s stock, valued at $8,636,659.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

AxoGen Stock Performance

NASDAQ:AXGN opened at $7.77 on Thursday. The stock’s fifty day moving average is $9.26 and its 200 day moving average is $7.03. The firm has a market capitalization of $335.74 million, a PE ratio of -14.94 and a beta of 1.07. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.14 and a current ratio of 2.89. AxoGen, Inc. has a fifty-two week low of $3.45 and a fifty-two week high of $10.83.

Hedge Funds Weigh In On AxoGen

Several hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its position in AxoGen by 590.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 509,214 shares of the medical equipment provider’s stock valued at $3,478,000 after acquiring an additional 435,481 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of AxoGen during the 4th quarter worth $427,000. Empire Financial Management Company LLC grew its position in shares of AxoGen by 17.3% during the 4th quarter. Empire Financial Management Company LLC now owns 70,350 shares of the medical equipment provider’s stock worth $480,000 after buying an additional 10,350 shares in the last quarter. Barclays PLC grew its position in shares of AxoGen by 143.9% during the 4th quarter. Barclays PLC now owns 69,877 shares of the medical equipment provider’s stock worth $477,000 after buying an additional 41,222 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its position in shares of AxoGen by 88.0% during the 4th quarter. Nuveen Asset Management LLC now owns 353,136 shares of the medical equipment provider’s stock worth $2,412,000 after buying an additional 165,310 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on AXGN. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $12.00 price target on shares of AxoGen in a report on Friday, January 19th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price target on shares of AxoGen in a report on Thursday, December 7th.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.